| Type | Julkinen osakeyhtiö |
|---|---|
| Traded as | OMX: ORNBV |
| Industry | Pharmaceutical industry |
| Founded | 1917 |
| Headquarters | Espoo, Finland |
| Key people | Timo Lappalainen (President and CEO), Hannu Syrjänen (Chairman) |
| Products | Pharmaceuticals, active pharmaceutical ingredients and diagnostic tests |
| Revenue | €849.9 million (2010)[1] |
| Operating income | €254.2 million (2010)[1] |
| Profit | €184.7 million (2010)[1] |
| Total assets | €745.8 million (end 2010)[1] |
| Total equity | €467.4 million (end 2010)[1] |
| Employees | 3,140 (average, 2010)[1] |
| Website | www.orion.fi |
Orion Corporation, founded in 1917 and headquartered at Espoo, Finland, is a Finnish company, which develops, manufactures and markets pharmaceuticals, active pharmaceutical ingredients and diagnostic tests for global markets. The company also has a large R&D unit in Turku.
Orion has annual net sales of approximately EUR 500 million; its class A and B shares are listed on the Helsinki Stock Exchange.
|
|
|||||